出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2023年5月
HLA タイピング市場 : テクノロジー［PCR（SSO、SSP、リアルタイム）、シーケンシング（NGS、サンガー）］、製品（機器、試薬、ソフトウェア）、用途（キメリズム、抗体スクリーニング）、エンドユーザー（病院、診断研究所、学術機関）、地域別 – 2028年までの世界予測
HLA Typing Market by Technology (PCR (SSO, SSP, Real Time), Sequencing (NGS, Sanger)), Product (Instrument, Reagent, Software), Application (Chimerism, Antibody Screening), End User (Hospital, Diagnolab, Academia) & Region – Global Forecast to 2028
| ページ数 | 217 |
| 図表数 | 217 |
| 種別 | 英文調査報告書 |
| 価格 |
The HLA typing market is projected to reach USD 2.1 billion in 2028 from USD 1.4 billion in 2022 with a CAGR of 6.5% during the forecast period. The need and strong demand for clinical diagnostic procedures that can provide early diagnosis of infectious diseases, graft rejections, autoimmune diseases, and cancer have supported rising research activities. According to the Journal of Human Genetics (2015), research on the human leukocyte antigen (HLA) molecule (involved in immunity) has benefitted greatly from NGS technologies. Thus, several high-throughput HLA-typing methods using NGS have been developed, as NGS technology enables complete HLA sequencing mechanisms, facilitating the understanding of HLA gene modulation, including transcription, regulation of gene expression, and epigenetics.
Thus, government organizations and private players increasingly support research activities that target gene profiling and cross-matching in prospective subjects.
“The molecular assay technologies segment to hold the largest share of the market in 2022”
In 2022, he molecular assay technologies segment was projected to account for the highest share. The high market share of the segment is credited to the profits of molecular assay technologies like real-time sample analysis multi-sample study capabilities, high procedural efficacy, , and low turnaround times.
“The reagents & consumables is holding the largest share of the market in 2022”
Based on product & service, The consumables & reagents segment reported for the highest share among all the three of the HLA typing market in 2022. The increasing use of reagents & consumables in HLA typing; the increasing acceptance of reagents & consumables in research studies; growing patient importance on early and effective treatment planning transplantation diagnosis over major geographies are predictable to determine market growth for this segment over the forecast period.
“The HLA Typing market in North America region is projected to witness the highest growth over the forecast period.”
North America reported the largest share of 45.0% of the HLA typing market in 2022. This highest share of North America is credited to the increased adoption of developed diagnostics tools, rising incidence and prevalence of chronic disorders in Canada and the US and growing technological developments.
While APAC is expected to witness significant growth in the coming years. The HLA typing market in the APAC region is expected to register a CAGR of 7.5% during the forecast period, primarily due to the growing number of hospitals in Asian countries and favorable government initiatives.
A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1–40%, Tier 2–30%, and Tier 3– 30%
• By Designation: C-level–27%, Director-level–18and Others–55%
• By Region: North America–35.3%, Europe–20%, Asia Pacific–15%, Latin America–10%, and the Middle East & Africa–5%
The prominent player in HLA typing market are Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (US), and bioMérieux S.A. (France). Other players in the market are Immucor, Inc. (US), Illumina, Inc. (US), Luminex Corporation (US), CareDx (US), Becton, Dickinson and Company (US), Hologic (US), GenDx (Netherlands), and Biofortuna (UK), among others
Research Coverage
This report studies the in HLA typing market based on product & service, technology, application, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will enable established and entrants/smaller firms to gauge the market’s pulse, which, in turn, would help them garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.
This report provides insights on the following pointers:
• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the microcatheter market.
• Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the microcatheter market..
• Market Development: Comprehensive information on lucrative emerging regions
• Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the microcatheter market.
• Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.
目次
1 INTRODUCTION 27
1.1 STUDY OBJECTIVES 27
1.2 MARKET DEFINITION 27
1.2.1 INCLUSIONS AND EXCLUSIONS 27
1.3 MARKET SCOPE 28
1.3.1 MARKETS COVERED 28
1.3.2 GEOGRAPHIES COVERED 28
1.3.3 YEARS CONSIDERED 29
1.4 CURRENCY CONSIDERED 29
1.5 STAKEHOLDERS 29
1.6 SUMMARY OF CHANGES 30
2 RESEARCH METHODOLOGY 31
2.1 RESEARCH DATA 31
FIGURE 1 HLA TYPING MARKET: RESEARCH METHODOLOGY 31
2.1.1 SECONDARY DATA 32
2.1.1.1 Key data from secondary sources 32
2.1.2 PRIMARY DATA 33
FIGURE 2 PRIMARY SOURCES 33
2.1.2.1 Key data from primary sources 34
2.1.2.2 Insights from primary experts 35
2.1.2.3 Breakdown of primary interviews 35
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 36
2.2 MARKET SIZE ESTIMATION 36
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 37
FIGURE 5 TOP-DOWN APPROACH 38
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 40
FIGURE 6 DATA TRIANGULATION METHODOLOGY 40
2.4 MARKET SHARE ESTIMATION 41
2.5 RESEARCH ASSUMPTIONS 41
2.6 LIMITATIONS 41
2.6.1 METHODOLOGY-RELATED LIMITATIONS 41
2.7 RISK ASSESSMENT 42
TABLE 1 LIMITATIONS AND ASSOCIATED RISKS 42
2.8 HLA TYPING MARKET: RECESSION IMPACT 42
3 EXECUTIVE SUMMARY 43
FIGURE 7 HLA TYPING MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) 43
FIGURE 8 HLA TYPING MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 44
FIGURE 9 HLA TYPING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 44
FIGURE 10 HLA TYPING MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 45
FIGURE 11 ASIA PACIFIC REGION TO DOMINATE MARKET DURING FORECAST PERIOD 46
4 PREMIUM INSIGHTS 47
4.1 HLA TYPING MARKET OVERVIEW 47
FIGURE 12 INCREASING NUMBER OF ORGAN TRANSPLANTATIONS AND RISING ADOPTION OF DONOR RECIPIENT CROSS-MATCHING TO DRIVE MARKET 47
4.2 HLA TYPING MARKET, BY DIAGNOSTIC APPLICATIONS, 2023 VS. 2028 (USD MILLION) 48
FIGURE 13 DONOR RECIPIENT CROSS-MATCHING SEGMENT TO DOMINATE DIAGNOSTIC APPLICATIONS DURING FORECAST PERIOD 48
4.3 HLA TYPING MARKET: ASIA PACIFIC, BY PRODUCT & SERVICE (2022) 49
FIGURE 14 REAGENTS & CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN CHINA 49
4.4 HLA TYPING MARKET: GEOGRAPHICAL SNAPSHOT 50
FIGURE 15 CHINA TO DOMINATE MARKET DURING FORECAST PERIOD 50
5 MARKET OVERVIEW 51
5.1 INTRODUCTION 51
5.2 MARKET DYNAMICS 51
FIGURE 16 HLA TYPING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 51
5.2.1 DRIVERS 52
5.2.1.1 Rising number of organ transplantation procedures 52
5.2.1.2 Rising technological advancements in HLA typing 52
5.2.1.3 Increasing funding investments for research activities 53
TABLE 2 PUBLIC-PRIVATE INVESTMENTS AND RESEARCH GRANTS FOR HLA TYPING PRODUCTS, 2019–2022 53
5.2.1.4 Growing prevalence of infectious diseases 53
5.2.2 RESTRAINTS 54
5.2.2.1 High cost of HLA typing products 54
TABLE 3 COST OF ASSAYS FOR KEY NGS AND PCR-BASED GENOMIC TESTS IN EUROPE (AS OF 2020) 54
5.2.2.2 Limited reimbursements for target procedures 55
5.2.3 OPPORTUNITIES 55
5.2.3.1 Rising adoption of cross-matching and chimerism testing procedures 55
5.2.3.2 Growing awareness of organ donations 56
5.2.4 CHALLENGES 56
5.2.4.1 Limited number of organ donations and long waiting lists for transplantations 56
5.2.4.2 Shortage of skilled professionals 56
5.3 PORTER’S FIVE FORCES ANALYSIS 57
TABLE 4 HLA TYPING MARKET: PORTER’S FIVE FORCES ANALYSIS 57
5.3.1 THREAT OF NEW ENTRANTS 57
5.3.2 THREAT OF SUBSTITUTES 57
5.3.3 BARGAINING POWER OF SUPPLIERS 57
5.3.4 BARGAINING POWER OF BUYERS 58
5.3.5 INTENSITY OF COMPETITIVE RIVALRY 58
5.4 REGULATORY ANALYSIS 58
5.4.1 NORTH AMERICA 58
5.4.1.1 US 58
TABLE 5 US FDA: MEDICAL DEVICE CLASSIFICATION 58
TABLE 6 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 59
5.4.1.2 Canada 59
TABLE 7 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 59
5.4.2 EUROPE 60
5.4.3 ASIA PACIFIC 60
5.4.3.1 Japan 60
TABLE 8 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PHARMACEUTICAL AND MEDICAL DEVICE AGENCY (PMDA) 61
5.4.3.2 China 61
TABLE 9 CHINA: CLASSIFICATION OF MEDICAL DEVICES 61
5.4.3.3 India 63
5.5 HLA TYPING MARKET: ECOSYSTEM MAPPING 64
FIGURE 17 ECOSYSTEM COVERAGE 64
5.6 VALUE CHAIN ANALYSIS 64
5.6.1 RESEARCH AND DEVELOPMENT 64
5.6.2 MANUFACTURING AND ASSEMBLY 65
5.6.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES 65
FIGURE 18 VALUE CHAIN ANALYSIS 65
5.7 SUPPLY CHAIN ANALYSIS 65
5.7.1 PROMINENT COMPANIES 65
5.7.2 SMALL AND MEDIUM-SIZED ENTERPRISES 65
FIGURE 19 SUPPLY CHAIN ANALYSIS 66
5.8 KEY STAKEHOLDERS AND BUYING CRITERIA 66
5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS 66
FIGURE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS 66
TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF HLA TYPING PRODUCTS 67
5.8.2 BUYING CRITERIA 67
FIGURE 21 KEY BUYING CRITERIA FOR HLA TYPING PRODUCTS 67
TABLE 11 KEY BUYING CRITERIA FOR HLA TYPING PRODUCTS 67
5.9 PATENT ANALYSIS 68
FIGURE 22 TOP 10 PATENT APPLICANTS FOR HLA TYPING 68
5.10 IMPACT OF RECESSION ON HLA TYPING MARKET 68
6 HLA TYPING MARKET, BY PRODUCT & SERVICE 69
6.1 INTRODUCTION 70
TABLE 12 HLA TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 70
6.2 REAGENTS & CONSUMABLES 70
6.2.1 WIDE APPLICATIONS OF MOLECULAR ASSAY TECHNIQUES TO DRIVE MARKET 70
TABLE 13 HLA TYPING MARKET FOR REAGENTS & CONSUMABLES, BY REGION, 2021–2028 (USD MILLION) 71
6.3 INSTRUMENTS 71
6.3.1 GROWING ADOPTION OF PCR AND NGS INSTRUMENTS AMONG CROS AND HOSPITALS TO FUEL MARKET 71
TABLE 14 HLA TYPING MARKET FOR INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION) 71
6.4 SOFTWARE & SERVICES 72
6.4.1 RISING DEMAND FOR AUTOMATION AND DIGITALIZATION IN LAB PROCEDURES TO DRIVE MARKET 72
TABLE 15 HLA TYPING MARKET FOR SOFTWARE & SERVICES, BY REGION, 2021–2028 (USD MILLION) 72
7 HLA TYPING MARKET, BY TECHNOLOGY 73
7.1 INTRODUCTION 74
TABLE 16 HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 74
7.2 MOLECULAR ASSAY TECHNOLOGIES 74
TABLE 17 HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 75
TABLE 18 HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 75
TABLE 19 HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY APPLICATION, 2021–2028 (USD MILLION) 76
TABLE 20 HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY END USER, 2021–2028 (USD MILLION) 76
TABLE 21 HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2021–2028 (USD MILLION) 76
7.2.1 PCR-BASED MOLECULAR ASSAYS 77
TABLE 22 HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2021–2028 (USD MILLION) 77
TABLE 23 HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY PRODUCT & SERVICE, 2021–2028(USD MILLION) 77
TABLE 24 HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY APPLICATION, 2021–2028 (USD MILLION) 78
TABLE 25 HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY END USER, 2021–2028 (USD MILLION) 78
TABLE 26 HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY REGION, 2021–2028 (USD MILLION) 78
7.2.1.1 Sequence-specific Primer-PCR 79
7.2.1.1.1 Expanding distribution channels of key PCR manufacturers to support market growth 79
TABLE 27 HLA TYPING MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR, BY REGION, 2021–2028 (USD MILLION) 79
7.2.1.2 Sequence-specific Oligonucleotide-PCR 79
7.2.1.2.1 Rising need for SSO-PCR-based molecular assays in disease diagnosis to drive market 79
TABLE 28 HLA TYPING MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY REGION, 2021–2028 (USD MILLION) 81
7.2.1.3 Real-time PCR 81
7.2.1.3.1 Increasing preference for genome-based molecular diagnostics to support market growth 81
TABLE 29 HLA TYPING MARKET FOR REAL-TIME PCR, BY REGION, 2021–2028 (USD MILLION) 81
7.2.1.4 Other PCR-based molecular assays 82
TABLE 30 HLA TYPING MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY REGION, 2021–2028 (USD MILLION) 82
7.2.2 SEQUENCING-BASED MOLECULAR ASSAYS 82
TABLE 31 HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2021–2028 (USD MILLION) 83
TABLE 32 HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 83
TABLE 33 HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY APPLICATION, 2021–2028 (USD MILLION) 83
TABLE 34 HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY END USER, 2021–2028 (USD MILLION) 84
TABLE 35 HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2021–2028 (USD MILLION) 84
7.2.2.1 Sanger sequencing 84
7.2.2.1.1 Rising end-user preference for low-cost and efficient DNA sequencing technology to drive segment growth 84
TABLE 36 HLA TYPING MARKET FOR SANGER SEQUENCING, BY REGION, 2021–2028 (USD MILLION) 85
7.2.2.2 Next-generation Sequencing 85
7.2.2.2.1 High scalability, low turnaround time, and high throughput capabilities to drive segment growth 85
TABLE 37 HLA TYPING MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2021–2028 (USD MILLION) 86
7.2.2.3 Other sequencing-based molecular assays 86
TABLE 38 HLA TYPING MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2021–2028 (USD MILLION) 86
7.3 NON-MOLECULAR ASSAY TECHNOLOGIES 87
7.3.1 HIGH PREFERENCE OF MOLECULAR-BASED TECHNIQUES TO RESTRAIN MARKET 87
TABLE 39 HLA TYPING MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 87
TABLE 40 HLA TYPING MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY APPLICATION, 2021–2028 (USD MILLION) 87
TABLE 41 HLA TYPING MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY END USER, 2021–2028 (USD MILLION) 88
TABLE 42 HLA TYPING MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2021–2028 (USD MILLION) 88
8 HLA TYPING MARKET, BY APPLICATION 89
8.1 INTRODUCTION 90
TABLE 43 HLA TYPING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 90
8.2 DIAGNOSTIC APPLICATIONS 90
TABLE 44 HLA TYPING MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 90
TABLE 45 HLA TYPING MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 91
8.2.1 DONOR-RECIPIENT CROSS-MATCHING 91
8.2.1.1 Rising need for histocompatibility cross-matching in organ transplantation to drive market 91
TABLE 46 HLA TYPING MARKET FOR DONOR-RECIPIENT CROSS-MATCHING, BY REGION, 2021–2028 (USD MILLION) 92
8.2.2 INFECTIOUS DISEASE TESTING 92
8.2.2.1 Rising burden of infectious diseases to drive adoption of HLA antigen screening 92
TABLE 47 HLA TYPING MARKET FOR INFECTIOUS DISEASE TESTING, BY REGION, 2021–2028 (USD MILLION) 93
8.2.3 CANCER DIAGNOSIS & PREVENTION 93
8.2.3.1 Wide availability of advanced NGS techniques to drive adoption of HLA typing in cancer diagnostics 93
TABLE 48 HLA TYPING MARKET FOR CANCER DIAGNOSIS & PREVENTION, BY REGION, 2021–2028 (USD MILLION) 93
8.2.4 TRANSFUSION THERAPY 94
8.2.4.1 Minimal risk of fatal disorders during blood transfusions to drive adoption of HLA typing 94
TABLE 49 HLA TYPING MARKET FOR TRANSFUSION THERAPY, BY REGION, 2021–2028(USD MILLION) 94
8.2.5 OTHER DIAGNOSTIC APPLICATIONS 94
TABLE 50 HLA TYPING MARKET FOR OTHER DIAGNOSTIC APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 95
8.3 RESEARCH APPLICATIONS 95
8.3.1 RISING FUNDING FOR RESEARCH AND EXPANDING APPLICATIONS OF HLA TYPING TO DRIVE MARKET 95
TABLE 51 HLA TYPING MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 96
9 HLA TYPING MARKET, BY END USER 97
9.1 INTRODUCTION 98
TABLE 52 HLA TYPING MARKET, BY END USER, 2021–2028 (USD MILLION) 98
9.2 COMMERCIAL SERVICE PROVIDERS 98
9.2.1 RISING ESTABLISHMENT OF REFERENCE LABORATORIES IN EMERGING ECONOMIES TO DRIVE MARKET 98
TABLE 53 HLA TYPING MARKET FOR COMMERCIAL SERVICE PROVIDERS, BY REGION, 2021–2028 (USD MILLION) 99
9.3 HOSPITALS AND TRANSPLANT CENTERS 99
9.3.1 INCREASING DEMAND FOR ADVANCED EQUIPMENT IN HOSPITALS TO DRIVE MARKET 99
TABLE 54 HLA TYPING MARKET FOR HOSPITALS AND TRANSPLANT CENTERS, BY REGION, 2021–2028 (USD MILLION) 99
9.4 RESEARCH LABORATORIES AND ACADEMIC INSTITUTES 100
9.4.1 RISING GOVERNMENT SUPPORT FOR CANCER RESEARCH TO BOOST MARKET GROWTH 100
TABLE 55 HLA TYPING MARKET FOR RESEARCH LABORATORIES AND ACADEMIC INSTITUTES, BY REGION, 2021–2028(USD MILLION) 100
10 HLA TYPING MARKET, BY REGION 101
10.1 INTRODUCTION 102
TABLE 56 HLA TYPING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 102
10.2 NORTH AMERICA 102
FIGURE 23 HLA TYPING MARKET: NORTH AMERICA SNAPSHOT 103
TABLE 57 NORTH AMERICA: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 103
TABLE 58 NORTH AMERICA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 104
TABLE 59 NORTH AMERICA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 104
TABLE 60 NORTH AMERICA: HLA TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 104
TABLE 61 NORTH AMERICA: HLA TYPING MARKET, BY APPLICATION 2021–2028 (USD MILLION) 105
TABLE 62 NORTH AMERICA: HLA TYPING MARKET, BY END USER, 2021–2028 (USD MILLION) 105
10.2.1 US 105
10.2.1.1 High volume of stem cell and bone marrow transplantation procedures to drive market 105
TABLE 63 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN US, 2021–2022 106
TABLE 64 NEW CANCER CASES IN US, 2021 106
TABLE 65 US: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 106
TABLE 66 US: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 106
TABLE 67 US: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 107
10.2.2 CANADA 107
10.2.2.1 High prevalence of cancer to drive adoption of HLA typing 107
TABLE 68 CANADA: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 107
TABLE 69 CANADA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 108
TABLE 70 CANADA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 108
10.3 EUROPE 108
TABLE 71 EUROPE: HLA TYPING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 72 EUROPE: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 109
TABLE 73 EUROPE: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 109
TABLE 74 EUROPE: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 110
TABLE 75 EUROPE: HLA TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 110
TABLE 76 EUROPE: HLA TYPING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 110
TABLE 77 EUROPE: HLA TYPING MARKET, BY END USER, 2021–2028 (USD MILLION) 111
10.3.1 GERMANY 111
10.3.1.1 Strong presence of established manufacturers for HLA typing products to drive market 111
TABLE 78 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN GERMANY, BY TYPE, 2020–2021 111
TABLE 79 TARGET DISEASE INCIDENCE IN GERMANY (2021) 112
TABLE 80 NEW CANCER CASES IN GERMANY, BY ORGAN (2021) 112
TABLE 81 GERMANY: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 112
TABLE 82 GERMANY: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 112
TABLE 83 GERMANY: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 113
10.3.2 UK 113
10.3.2.1 Rising prevalence of autoimmune diseases to drive market 113
TABLE 84 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN UK, 2021–2022 113
TABLE 85 TARGET DISEASE INCIDENCE IN UK, 2021 114
TABLE 86 NEW CANCER CASES IN UK, 2021 114
TABLE 87 UK: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 114
TABLE 88 UK: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 114
TABLE 89 UK: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 115
10.3.3 FRANCE 115
10.3.3.1 Rising organ rejection rate to drive market 115
TABLE 90 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN FRANCE, 2021–2022 115
TABLE 91 NEW CANCER CASES IN FRANCE, 2021 116
TABLE 92 FRANCE: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 116
TABLE 93 FRANCE: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, 2021–2028 (USD MILLION) 116
TABLE 94 FRANCE: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES ASSAYS, BY TYPE, 2021–2028 (USD MILLION) 117
10.3.4 ITALY 117
10.3.4.1 Increasing acceptance of molecular assay technologies for personalized medicine to drive market 117
TABLE 95 ITALY: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 117
TABLE 96 ITALY: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 118
TABLE 97 ITALY: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 118
10.3.5 SPAIN 118
10.3.5.1 Rising number of solid-organ transplantation procedures to support market growth 118
TABLE 98 SPAIN: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 119
TABLE 99 SPAIN: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 119
TABLE 100 SPAIN: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 119
10.3.6 REST OF EUROPE 120
TABLE 101 REST OF EUROPE: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 120
TABLE 102 REST OF EUROPE: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 120
TABLE 103 REST OF EUROPE: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES ASSAYS, BY TYPE, 2021–2028 (USD MILLION) 121
10.4 ASIA PACIFIC 121
FIGURE 24 HLA TYPING MARKET: ASIA PACIFIC SNAPSHOT 122
TABLE 104 ASIA PACIFIC: HLA TYPING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 105 ASIA PACIFIC: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 123
TABLE 106 ASIA PACIFIC: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 123
TABLE 107 ASIA PACIFIC: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 123
TABLE 108 ASIA PACIFIC: HLA TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 124
TABLE 109 ASIA PACIFIC: HLA TYPING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 124
TABLE 110 ASIA PACIFIC: HLA TYPING MARKET, BY END USER, 2021–2028 (USD MILLION) 124
10.4.1 CHINA 125
10.4.1.1 Rising adoption of HLA typing for donor-recipient screening to drive market 125
TABLE 111 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN CHINA, 2021–2022 125
TABLE 112 NEW CANCER CASES IN CHINA, 2021 125
TABLE 113 CHINA: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 125
TABLE 114 CHINA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 126
TABLE 115 CHINA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 126
10.4.2 INDIA 126
10.4.2.1 Government initiatives to provide free availability of HLA typing products to drive market 126
TABLE 116 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN INDIA, 2021–2022 127
TABLE 117 NEW CANCER CASES IN INDIA, 2021 127
TABLE 118 INDIA: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 127
TABLE 119 INDIA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 128
TABLE 120 INDIA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 128
10.4.3 JAPAN 128
10.4.3.1 Increasing budgetary allocations for healthcare to support market growth 128
TABLE 121 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN JAPAN, 2021–2022 129
TABLE 122 NEW CANCER CASES IN JAPAN, 2021 129
TABLE 123 JAPAN: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 129
TABLE 124 JAPAN: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 130
TABLE 125 JAPAN: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 130
10.4.4 AUSTRALIA 130
10.4.4.1 Rising prevalence of coeliac disease to drive adoption of HLA typing 130
TABLE 126 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN AUSTRALIA, 2021–2022 131
TABLE 127 NEW CANCER CASES IN AUSTRALIA, 2021 131
TABLE 128 AUSTRALIA: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 131
TABLE 129 AUSTRALIA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 132
TABLE 130 AUSTRALIA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 132
10.4.5 SOUTH KOREA 132
10.4.5.1 Rising adoption of next-generation exome sequencing to drive market 132
TABLE 131 SOUTH KOREA: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 133
TABLE 132 SOUTH KOREA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 133
TABLE 133 SOUTH KOREA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES ASSAYS, BY TYPE, 2021–2028 (USD MILLION) 133
10.4.6 REST OF ASIA PACIFIC 134
TABLE 134 REST OF ASIA PACIFIC: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 134
TABLE 135 REST OF ASIA PACIFIC: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 134
TABLE 136 REST OF ASIA PACIFIC: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES ASSAYS, BY TYPE, 2021–2028 (USD MILLION) 135
10.5 LATIN AMERICA 135
TABLE 137 LATIN AMERICA: HLA TYPING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 138 LATIN AMERICA: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 136
TABLE 139 LATIN AMERICA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 136
TABLE 140 LATIN AMERICA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 136
TABLE 141 LATIN AMERICA: HLA TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 137
TABLE 142 LATIN AMERICA: HLA TYPING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 137
TABLE 143 LATIN AMERICA: HLA TYPING MARKET, BY END USER, 2021–2028 (USD MILLION) 137
10.5.1 BRAZIL 138
10.5.1.1 Supportive government regulations for adoption of advanced technologies to drive market 138
TABLE 144 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN BRAZIL, 2021–2022 138
TABLE 145 NEW CANCER CASES IN BRAZIL, 2021 138
TABLE 146 BRAZIL: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 139
TABLE 147 BRAZIL: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 139
TABLE 148 BRAZIL: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 139
10.5.2 MEXICO 140
10.5.2.1 Improving accessibility and affordability of healthcare services to support market growth 140
TABLE 149 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN MEXICO, 2021–2022 140
TABLE 150 NEW CANCER CASES IN MEXICO, 2021 140
TABLE 151 MEXICO: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 140
TABLE 152 MEXICO: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 141
TABLE 153 MEXICO: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 141
10.5.3 REST OF LATIN AMERICA 141
TABLE 154 REST OF LATIN AMERICA: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 142
TABLE 155 REST OF LATIN AMERICA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 142
TABLE 156 REST OF LATIN AMERICA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 142
10.6 MIDDLE EAST AND AFRICA 143
10.6.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO FUEL MARKET 143
TABLE 157 MIDDLE EAST & AFRICA: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 143
TABLE 158 MIDDLE EAST & AFRICA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 143
TABLE 159 MIDDLE EAST & AFRICA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES ASSAYS, BY TYPE, 2021–2028 (USD MILLION) 143
TABLE 160 MIDDLE EAST & AFRICA: HLA TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 144
TABLE 161 MIDDLE EAST & AFRICA: HLA TYPING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 144
TABLE 162 MIDDLE EAST & AFRICA: HLA TYPING MARKET, BY END USER, 2021–2028 (USD MILLION) 145
11 COMPETITIVE LANDSCAPE 146
11.1 INTRODUCTION 146
11.2 STRATEGIES ADOPTED BY KEY PLAYERS 146
TABLE 163 HLA TYPING MARKET: OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 147
11.3 MARKET SHARE ANALYSIS 147
FIGURE 25 HLA TYPING MARKET SHARE ANALYSIS, BY KEY PLAYER (2021) 147
11.4 COMPETITIVE LEADERSHIP MAPPING 148
11.4.1 STARS 149
11.4.2 EMERGING LEADERS 149
11.4.3 PERVASIVE PLAYERS 149
11.4.4 PARTICIPANTS 150
FIGURE 26 HLA TYPING MARKET: COMPETITIVE LEADERSHIP MAPPING (2021) 150
11.5 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2021) 151
11.5.1 PROGRESSIVE COMPANIES 151
11.5.2 RESPONSIVE COMPANIES 151
11.5.3 DYNAMIC COMPANIES 151
11.5.4 STARTING BLOCKS 151
FIGURE 27 HLA TYPING MARKET: COMPANY EVALUATION MATRIX FOR SMES/STARTUPS, 2021 152
11.6 COMPETITIVE BENCHMARKING 152
TABLE 164 HLA TYPING MARKET: PRODUCT ANALYSIS FOR KEY PLAYERS 152
TABLE 165 HLA TYPING MARKET: APPLICATION FOOTPRINT ANALYSIS FOR KEY PLAYERS 153
TABLE 166 HLA TYPING MARKET: REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS 154
11.7 COMPETITIVE SCENARIO 155
11.7.1 PRODUCT LAUNCHES 155
TABLE 167 HLA TYPING MARKET: PRODUCT LAUNCHES (2019–2022) 155
11.7.2 DEALS 156
TABLE 168 HLA TYPING MARKET: DEALS (2019–2022) 156
12 COMPANY PROFILES 158
12.1 KEY PLAYERS 158
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 BD 158
TABLE 169 BD: COMPANY OVERVIEW (2021) 158
FIGURE 28 BD: COMPANY SNAPSHOT (2021) 159
12.1.2 BIO-RAD LABORATORIES, INC. 162
TABLE 170 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW (2021) 162
FIGURE 29 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021) 163
12.1.3 F. HOFFMAN-LA ROCHE LTD. 167
TABLE 171 F. HOFFMAN-LA ROCHE LTD: COMPANY OVERVIEW (2021) 167
FIGURE 30 F. HOFFMAN-LA ROCHE LTD: COMPANY SNAPSHOT (2021) 168
12.1.4 CAREDX, INC. 172
TABLE 172 CAREDX, INC.: COMPANY OVERVIEW (2021) 172
FIGURE 31 CAREDX, INC.: COMPANY SNAPSHOT (2021) 173
12.1.5 HOLOGIC, INC. 176
TABLE 173 HOLOGIC, INC.: COMPANY OVERVIEW (2021) 176
FIGURE 32 HOLOGIC, INC.: COMPANY SNAPSHOT (2021) 177
12.1.6 ILLUMINA, INC. 179
TABLE 174 ILLUMINA, INC.: COMPANY OVERVIEW (2021) 179
FIGURE 33 ILLUMINA, INC.: COMPANY SNAPSHOT (2021) 180
12.1.7 IMMUCOR, INC. 183
TABLE 175 IMMUCOR, INC.: COMPANY OVERVIEW (2021) 183
FIGURE 34 IMMUCOR, INC.: COMPANY SNAPSHOT (2021) 184
12.1.8 OMIXON INC. 188
TABLE 176 OMIXON INC.: COMPANY OVERVIEW (2021) 188
12.1.9 QIAGEN N.V. 190
TABLE 177 QIAGEN N.V.: COMPANY OVERVIEW (2021) 190
FIGURE 35 QIAGEN N.V.: COMPANY SNAPSHOT (2021) 191
12.1.10 TAKARA BIO INC. 197
TABLE 178 TAKARA BIO INC.: COMPANY OVERVIEW (2021) 197
FIGURE 36 TAKARA BIO, INC: COMPANY SNAPSHOT (2021) 197
12.1.11 THERMO FISHER SCIENTIFIC 199
TABLE 179 THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW (2021) 199
FIGURE 37 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2021) 200
12.1.12 BIOFORTUNA LIMITED 204
12.1.13 GENDX 205
TABLE 180 GENDX: COMPANY OVERVIEW (2021) 205
12.2 OTHER PLAYERS 207
12.2.1 FUJIREBIO 207
12.2.2 CREATIVE BIOLABS 207
12.2.3 ALPHA BIOTECH LIMITED 208
12.2.4 BAG DIAGNOSTICS GMBH 209
12.2.5 HANSA BIOPHARMA AB 210
12.2.6 HISTOGENETICS LLC 210
12.2.7 PACBIO 211
12.2.8 TBG DIAGNOSTICS LIMITED 212
12.2.9 INNO-TRAIN DIAGNOSTIK GMBH 212
12.2.10 KRISHGEN BIOSYSTEMS 213
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 214
13.1 DISCUSSION GUIDE 214
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 220
13.3 CUSTOMIZATION OPTIONS 222
13.4 RELATED REPORTS 222
13.5 AUTHOR DETAILS 223